Lung Cancer | Specialty

Manochakian Calls for Repeat Genomic Testing Upon Osimertinib Progression in EGFR+ NSCLC

December 20th 2020

Rami Manochakian, MD, discusses the role of osimertinib in patients with EGFR-mutated NSCLC, strategies for treatment following progression on the third-generation TKI, and ongoing research efforts to further improve care.

FDA Approves Adjuvant Osimertinib for EGFR+ NSCLC

December 18th 2020

December 18, 2020 - The FDA has approved osimertinib for use as an adjuvant treatment following tumor resection in patients with non–small cell lung cancer whose tumors harbor EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test.

Sarah Cannon Promotes Melissa Johnson to Program Director, Lung Cancer Research

December 18th 2020

December 18, 2020 - Sarah Cannon announced the promotion of Melissa Johnson, MD, to Program Director of Lung Cancer Research.

Borghaei and Gunuganti Break Down the Elements of Treatment Selection in NSCLC

December 17th 2020

In our exclusive interview, Dr. Borghaei and Dr. Gunuganti discuss patient selection for frontline immunotherapy, combination immunotherapy, and chemoimmunotherapy in NSCLC, the importance of PD-L1 expression, and emerging agents that are coming down the pike.

Vopratelimab/JTX-4014 to be Evaluated in Phase 2 Study for Immunotherapy-Naïve NSCLC

December 17th 2020

December 17, 2020 - Jounce Therapeutics will evaluate its lead agent vopratelimab in combination with the anti–PD-1 monoclonal antibody JTX-4014, in patients with non-small cell lung cancer who have not received immunotherapy.

FDA Approval Sought for Sotorasib for KRAS G12C–Mutated Advanced or Metastatic NSCLC

December 17th 2020

December 16, 2020 - A new drug application has been submitted to the FDA for sotorasib for the treatment of patients with KRAS G12C–mutant locally advanced or metastatic non–small cell lung cancer, as determined by an FDA-approved test, after at least 1 previous systemic therapy.

Immunotherapy Agents Drive Frontline Treatment Strategies in Advanced NSCLC

December 16th 2020

Several immunotherapeutic options are available for non–small cell lung cancer (NSCLC), allowing decisions to be made based on histology, PD-L1 expression, and patient preference in regard to their treatment goals. Looking ahead, there may also be efficacy in moving immunotherapy drugs up into the resectable, early-stage setting

Dr. Herbst on Biomarkers for Immunotherapy Response in NSCLC

December 16th 2020

Roy S. Herbst, MD, PhD, discusses biomarkers for immunotherapy response that are currently under investigation in non–small cell lung cancer (NSCLC).

Dr. Goldberg on the Evolving Role of Immunotherapy in NSCLC

December 16th 2020

Sarah B. Goldberg, MD, MPH, discusses the evolving role of immunotherapy in non–small cell lung cancer.

Fixed-Dose Durvalumab Nears EU Approval for Unresectable NSCLC

December 15th 2020

December 15, 2020 - The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion for an additional dosing option of durvalumab, a fixed dose of 1500 mg every 4 weeks, in the approved indication of locally advanced, unresectable non–small cell lung cancer in adults whose tumors have a PD-L1 expression of at least 1% and who did not have progressive disease after platinum-based chemoradiation treatment.

Halmos Zeroes in on Year Ahead for Lung Cancer Treatment

December 15th 2020

Balazs Halmos, MD discusses the year 2021 and how it will encompass a bigger focus on neoadjuvant and adjuvant trials, more novel molecular compounds for more select subgroups, and a migration of circulating tumor DNA into a more minimal residual disease–based setting.

Learning to Tailor Targeted and Immune Therapy in Lung Cancer

December 14th 2020

Faculty of the MedStar Georgetown University Hospital-hosted Institutional Perspectives in Cancer webinar on lung cancer spotlight key advances made with targeted therapies in lung cancer, the ways in which immunotherapy has complicated treatment decisions, and more!

Dr. Weber on the Toxicities Associated With Immunotherapy in Lung Cancer

December 14th 2020

Jeffrey S. Weber, MD, PhD, discusses the toxicities associated with immunotherapy in lung cancer.

Immunotherapy Finds a Role in Frontline Small Cell Lung Cancer and Mesothelioma

December 14th 2020

Checkpoint inhibitors have failed to improve progression-free survival and overall survival as second-line therapy and maintenance therapy in small cell lung cancer, but this class of agents continue to show encouraging activity worthy of a paradigm shift up front.

Ongoing Research in Extensive-Stage Small Cell Lung Cancer

December 11th 2020

Treatment After Progression on Front-Line Therapy in Extensive-Stage Small Cell Lung Cancer

December 11th 2020

First-Line Approach for Treating Extensive-Stage Small Cell Lung Cancer

December 11th 2020

Results from the CASPIAN Trial for Extensive-Stage Small Cell Lung Cancer

December 11th 2020

Results from the IMpower133 Trial for Extensive-Stage Small Cell Lung Cancer

December 11th 2020

Advances in Extensive-Stage Small Cell Lung Cancer

December 11th 2020